Clinical trials: Hypertension, Uncontrolled
Uncontrolled Hypertension
BAROSTIM NEO Hypertension Pivotal Trial
The purpose of this clinical investigation (NCT01679132) is to assess the long-term safety and efficacy of the BAROSTIM NEO System in subjects currently participating in the BAROSTIM Hypertension Pivotal Trial (G120137).
- Trial name
- NCT01679132
- Testing
- BAROSTIM NEO System and Medical Management
- Where
- 11 sites in United States
- Volunteers
- 10 people
- Sponsor
- CVRx, Inc.
Pulmonary Hypertension
Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
This is an open-label, uncontrolled, prospective long-term observation of Specific Drug in the treatment of patients with pulmonary hypertension up to 4 years.
- Trial name
- OPTION (NCT01389271)
- Testing
- Ventavis inhaled (Iloprost, BAYQ6256)
- Where
- Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Bayer
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Uncontrolled Hypertension
Feasibility Study of Renal Denervation for the Treatment of Resistant Hypertension
The aim of this study is to assess the potential therapeutic benefit of catheter-based renal sympathetic denervation using therapeutic unfocussed ultrasound in a single-arm feasibility trial.
- Trial name
- SoundITV (NCT01865591)
- Testing
- Ultrasound-based Renal Denervation
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Sound Interventions, Inc.
Hypertension
Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients
The primary objective was to determine the effects of the Gastrointestinal Therapeutic System (GITS) formulation of Doxazosin when used in combination therapy with the 5 major classes of antihypertensive agents as measure by…
- Trial name
- NCT00646841
- Testing
- Doxazosin gastrointestinal therapeutic system (GITS)
- Where
- 7 sites in Italy, Spain and 1 more
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension
This study is designed to evaluate the efficacy and safety of the combination valsartan with hydrochlorothiazide and amlodipine in hypertensive patients previously treated with valsartan with hydrochlorothiazide and remaining…
- Trial name
- NCT00400777
- Testing
- Valsartan, hydrochlorothiazide and amlodipine
- Where
- Brazil
- Volunteers
- 460 people
- Sponsor
- Novartis
Hypertension
Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus
The aim of this post-marketing observational study (PMOS) is to provide data on the effectiveness and tolerability of Tarka in patients with a high risk of developing diabetes mellitus, as prescribed by the physicians in a…
- Trial name
- TARDIA (NCT01079195)
- Where
- 898 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 15,436 people
- Sponsor
- Abbott
Chronic Kidney Diseases
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage…
- Trial name
- Clarion-CKD (NCT04968184)
- Testing
- KBP-5074
- Where
- 215 sites in United States, Australia and 20 more
- Volunteers
- 652 people
- Sponsor
- KBP Biosciences
Hypertension, Uncontrolled Hypertension
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
- Trial name
- NCT07090161
- Testing
- iloperidone
- Where
- 28 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vanda Pharmaceuticals
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
This study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.
- Trial name
- NCT00277472
- Testing
- Valsartan/Hydrochlorothiazide, HCTZ
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novartis
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.
Uncontrolled Stage 2 Hypertension
REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /
This is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System in subjects with uncontrolled stage 2 hypertension in order to assess the safety and effectiveness…
- Trial name
- REDUCED (NCT05372679)
- Testing
- Renal denervation
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- SoniVie Inc.
Hypertension
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
The purpose of this study is to evaluate the blood pressure (BP)-lowering efficacy of tonlamarsen in adult participants who, despite taking 2 or more antihypertensive medications, have not achieved their target blood pressure…
- Trial name
- NCT06864104
- Testing
- Tonlamarsen
- Where
- 39 sites in United States
- Volunteers
- 206 people
- Sponsor
- Kardigan, Inc.
Hypertension
Renal Artery DenervatIon Using Radial accesS in Uncontrolled HyperTensioN
Non-inferiority, prospective, multi-center, international, post-market, randomized (1:1) clinical trial in patients with uncontrolled hypertension to compare the safety and efficacy of radio frequency renal denervation using…
- Trial name
- RADIUS-HTN (NCT05234788)
- Testing
- Transfemoral Renal Denervation, Transradial Renal Denervation
- Where
- 11 sites in France, Germany and 1 more
- Volunteers
- 90 people
- Sponsor
- Shanghai AngioCare Medical
Hypertension, Resistant Hypertension
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
- Conditions
- Hypertension, Resistant Hypertension, Uncontrolled Hypertension
- Trial name
- NCT07833098
- Testing
- VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Arterial Hypertension
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients
- Trial name
- NCT01071681
- Testing
- Telmisartan (Kinzal/Pritor, BAY68-9291)
- Where
- France
- Volunteers
- 1,589 people
- Sponsor
- Bayer
Hypertension, Vascular Diseases
SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study
The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the absence of antihypertensive medications.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT02439749
- Testing
- Symplicity Spyral™ multi-electrode renal denervation system
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 366 people
- Sponsor
- Medtronic Vascular
Hypertension, Hypertension, Resistant to Conventional Therapy
RADIANCE Continued Access Protocol
RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects…
- Conditions
- Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE CAP (NCT05017935)
- Testing
- Renal Denervation
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- ReCor Medical, Inc.
Hypertension, Pulmonary
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as…
- Trial name
- RIALTO (NCT02759419)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 9 sites in France, South Korea
- Volunteers
- 18 people
- Sponsor
- Bayer
Uncontrolled or Resistant Hypertension
A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.
The study is being conducted to evaluate the efficacy and safety of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension.
- Trial name
- NCT07708441
- Testing
- HRS-1780 tablet
- Where
- 2 sites in China
- Volunteers
- 914 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.